Stockscreener 앱 받기
26.30
0.69%
0.18
시장 영업 전:
26.25
-0.05
-0.19%
전일 마감가:
$26.12
열려 있는:
$26.45
하루 거래량:
1.71M
Relative Volume:
0.85
시가총액:
$2.59B
수익:
$672.72M
순이익/손실:
$-575.44M
주가수익비율:
-4.5064
EPS:
-5.8361
순현금흐름:
$-487.00M
1주 성능:
+6.01%
1개월 성능:
+12.88%
6개월 성능:
-20.90%
1년 성능:
-25.09%
1일 변동 폭
$26.21
$27.42
1주일 범위
$24.23
$27.42
52주 변동 폭
$18.29
$42.37
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
26.30 | 2.57B | 672.72M | -575.44M | -487.00M | -5.8361 |
VRTX
Vertex Pharmaceuticals Inc
|
435.17 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.77 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.28 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.84 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.75 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
GTX-102 data show continued developmental gains in Angelman - Angelman Syndrome News
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: Ultragenyx Q1 2026 sees revenue miss, stock rises - Investing.com Nigeria
Number of shareholders of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Number of shareholders of Ultragenyx Pharmaceutical, Inc. – FWB:UP0 - TradingView
Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Is Ultragenyx (RARE) Reaffirming 2026–2027 Guidance Enough To Offset Its Widening Losses? - Yahoo Finance
RARE SEC FilingsUltragenyx Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
Vanguard Group Inc. Buys 131,087 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Ultragenyx Pharmaceutical (RARE) Is Up 5.8% After Reaffirming 2026 Outlook Despite Wider Losses – What's Changed - Sahm
Rare Q1 loss wider than expected, sales down Y/Y on seasonal effect - msn.com
RARE Maintained by Wedbush -- Price Target Lowered to $26 - GuruFocus
RARE Maintained by Guggenheim -- Price Target Lowered to $43 - GuruFocus
Guggenheim Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00 - MarketBeat
Ultragenyx to Present at Bank of America Healthcare Conference on May 13, 2026 - geneonline.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2026 Earnings Call Transcript - Insider Monkey
Rare disease families find roadmap to drug development at bootcamps - CNBC
Ultragenyx Pharmaceutical (RARE) Heavy Q1 EPS Loss Tests Bulls Profitability Timeline Narrative - Sahm
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Ultragenyx Earnings Call: Growth, Gene Therapy and Risk - TipRanks
Ultragenyx Pharmaceutical Inc. 2024 SEC Filing: Financial Information, Forward-Looking Statements, and Market Risks - Minichart
Ultragenyx investors can watch CFO at Bank of America panel May 12 - Stock Titan
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference - The Manila Times
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares - Investing.com India
Ultragenyx EVP and chief medical officer Crombez sells $8,586 in shares By Investing.com - Investing.com South Africa
Ultragenyx (NASDAQ: RARE) CMO sells shares to cover RSU taxes - Stock Titan
Ultragenyx outlines $730M-$760M 2026 revenue as it targets two gene therapy PDUFAs in August and September - MSN
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect - Yahoo Finance
Wells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Two FDA decisions by September put Ultragenyx gene therapies in focus - Stock Titan
Wedbush Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Privium Fund Management B.V. - MarketBeat
Ultragenyx Pharmaceutical Q1 Loss Widens, Revenue Falls; Shares Down Pre-Bell - marketscreener.com
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS - MarketBeat
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts By Investing.com - Investing.com Canada
Earnings call transcript: Ultragenyx Q1 2026 results miss forecasts - Investing.com
Ultragenyx (NASDAQ: RARE) Q1 loss widens as R&D and restructuring costs rise - Stock Titan
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript - Benzinga
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ultragenyx Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ULTRAGENYX PHARMACEUTICAL ($RARE) Releases Q1 2026 Earnings - Quiver Quantitative
Ultragenyx: Q1 Earnings Snapshot - marketscreener.com
Gene therapy reviews and Q1 2026 results at Ultragenyx (RARE) - Stock Titan
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update - The Manila Times
Earnings Flash (RARE) Ultragenyx Pharmaceutical Inc. Reports Q1 Revenue $136.0M, Vs. FactSet Est of $158.4M - Moomoo
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.70%
2.51%
자본화:
|
볼륨(24시간):